Some individuals taking Wegovy (semaglutide 2.4 mg) have anecdotally reported changes in body odour, though this is not listed as an established side effect in the Summary of Product Characteristics. Wegovy is a GLP-1 receptor agonist licensed by the MHRA for weight management in adults with obesity or overweight with weight-related comorbidities. Whilst no confirmed link exists between Wegovy and body odour in clinical trials, metabolic changes during weight loss—such as fat breakdown releasing ketones—may indirectly affect body odour. Gastrointestinal side effects and altered dietary patterns could also play a role. This article explores potential mechanisms, practical management strategies, and when to seek medical advice regarding body odour concerns whilst taking Wegovy.
Quick Answer: Body odour is not an established side effect of Wegovy, though some individuals anecdotally report changes potentially linked to metabolic shifts during weight loss rather than the medication itself.
Wegovy (semaglutide 2.4 mg) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with weight-related comorbidities. Whilst body odour is not listed as an established side effect in the official Summary of Product Characteristics (SmPC), some individuals have anecdotally reported changes in body odour during treatment. It is important to understand that there is no confirmed link between Wegovy and body odour changes in clinical trials or post-marketing surveillance.
Several indirect mechanisms might potentially explain why some individuals notice alterations in body odour whilst taking Wegovy, though these remain hypothetical. The medication works by mimicking the GLP-1 hormone, which slows gastric emptying, reduces appetite, and promotes weight loss. These metabolic changes can affect how the body processes and eliminates waste products. As the body breaks down stored fat during weight loss, ketones and other metabolic by-products may be released. This can sometimes lead to changes in breath odour (a fruity or acetone smell) rather than body odour specifically, and is a phenomenon sometimes observed during any significant weight loss, regardless of the method used.
Additionally, Wegovy commonly causes gastrointestinal side effects such as nausea, vomiting, diarrhoea, and constipation, which affect a substantial proportion of users according to the SmPC. These digestive changes may potentially influence dietary patterns or hydration status. Increased sweating due to physical activity—often increased as part of a weight management programme—may also make body odour more noticeable. If you are concerned about body odour changes whilst taking Wegovy, it is worth discussing this with your healthcare provider to rule out other potential causes and receive personalised advice.
If you notice changes in body odour whilst taking Wegovy, several practical strategies can help manage this concern effectively. Maintaining excellent personal hygiene is the cornerstone of odour management. The NHS recommends regular washing with soap and water, particularly focusing on areas prone to sweating such as the underarms, groin, and feet, which can significantly reduce bacterial growth that contributes to odour. Ensure you dry these areas thoroughly, as bacteria thrive in moist environments.
Hydration plays a crucial role in managing body odour during weight loss. Drinking adequate water—typically 6 to 8 glasses of fluid daily as recommended by the NHS—helps flush metabolic waste products from your system. Proper hydration also supports managing the gastrointestinal side effects commonly experienced with Wegovy, potentially reducing indirect contributors to odour concerns.
Dietary modifications may prove beneficial for some individuals, though evidence is limited. Some people find certain foods may intensify their body odour, including foods high in sulphur compounds, strong spices, or alcohol. Increasing your intake of fresh fruits, vegetables, and whole grains may help support your weight loss goals and improve digestive comfort.
Clothing choices matter significantly. Opt for natural, breathable fabrics like cotton or moisture-wicking materials that allow sweat to evaporate rather than accumulate. Change clothes daily and wash workout attire after each use. Using high-strength aluminium chloride antiperspirants (containing 10-20% aluminium chloride), applied at night to clean, dry skin, can reduce sweating more effectively than standard deodorants. Many of these products are available over the counter in pharmacies. If over-the-counter products prove insufficient, your GP can advise on other options or consider referral to a dermatologist if excessive sweating (hyperhidrosis) is suspected.
Mounjaro® is the most innovative GLP-1 medication proven to dramatically curb appetite, hunger, and cravings to help professional men achieve substantial weight loss.
Start Here
Wegovy® is a weekly injectable GLP-1 medication with proven effectiveness in reducing appetite, hunger, and cravings to help busy professionals lose significant weight.
Start HereWhilst body odour changes alone rarely indicate a serious medical problem, certain circumstances warrant prompt discussion with your GP or prescribing clinician. Sudden, severe changes in body odour—particularly if accompanied by other symptoms—may signal an underlying condition requiring investigation. If you have diabetes and notice a sweet, fruity odour (particularly on your breath), this could potentially indicate diabetic ketoacidosis, which requires urgent medical assessment.
You should contact your GP if body odour changes are accompanied by:
Persistent gastrointestinal symptoms such as nausea or vomiting
Signs of dehydration including dark urine, dizziness, reduced urination, or extreme thirst
Unexplained fever, night sweats, or weight loss exceeding expected rates, which could suggest infection or other medical conditions
Skin changes such as rashes, excessive sweating, or fungal infections in body folds
Mood changes or anxiety related to body odour concerns affecting your quality of life
According to the Wegovy SmPC, you should seek urgent medical attention if you experience severe, persistent abdominal pain (with or without vomiting) which could indicate pancreatitis, or upper right abdominal pain, fever, nausea and yellowing of the skin or eyes which may suggest gallbladder problems.
Your prescriber will review your progress, side effects, and overall tolerability regularly in line with local specialist weight management service protocols and NICE guidance (TA875). Do not discontinue Wegovy without medical advice, as your clinician may suggest dose adjustments, additional investigations, or alternative management strategies. Remember that most side effects often improve as your body adjusts to the medication over the first few weeks to months of treatment.
Understanding the full side effect profile of Wegovy helps patients make informed decisions and recognise when to seek medical attention. Gastrointestinal effects are the most frequently reported adverse reactions according to the SmPC, with specific frequencies from clinical trials including nausea (approximately 44%), diarrhoea (30%), vomiting (24%), and constipation (24%). These symptoms typically emerge when initiating treatment or increasing the dose, and often diminish over time as the body adapts. Eating smaller, more frequent meals and avoiding high-fat foods can help manage these effects.
Injection site reactions such as redness, itching, or mild discomfort occur in some patients. Rotating injection sites between the abdomen, thigh, and upper arm, as instructed in the SmPC, minimises this risk. Follow the administration guidance provided with your medication.
Hypoglycaemia (low blood sugar) is uncommon with Wegovy alone but may occur if you are taking other diabetes medications concurrently, particularly insulin or sulphonylureas. Symptoms include trembling, sweating, confusion, and palpitations. If you have type 2 diabetes, your doctor may need to adjust other medications when starting Wegovy.
Gallbladder problems, including gallstones and cholecystitis, have been reported with GLP-1 receptor agonists. Contact your GP immediately if you experience severe abdominal pain, particularly in the upper right area, especially if accompanied by fever, nausea, or yellowing of the skin or eyes.
Other effects include:
Fatigue and dizziness, particularly during the initial weeks
Headache, usually mild and self-limiting
Increased heart rate, typically a modest elevation
Hair thinning, which may occur with rapid weight loss from any cause (telogen effluvium) rather than as a direct effect of the medication
Rare but serious side effects include pancreatitis (severe, persistent abdominal pain radiating to the back), thyroid C-cell tumours (shown in rodent studies; human relevance unknown), and acute kidney injury. The MHRA and EMA continue to monitor the safety profile of semaglutide. Always report unexpected or concerning symptoms to your healthcare provider, and utilise the Yellow Card Scheme (yellowcard.mhra.gov.uk) to report suspected side effects directly to the MHRA, contributing to ongoing medication safety surveillance.
No, body odour is not listed as an established side effect in the Wegovy Summary of Product Characteristics. Some individuals anecdotally report changes, but no confirmed link exists in clinical trials or post-marketing surveillance.
Metabolic changes during weight loss may release ketones and other by-products as stored fat breaks down. Gastrointestinal side effects and altered dietary patterns associated with Wegovy treatment may also indirectly contribute to odour changes.
Contact your GP if body odour changes are accompanied by persistent vomiting, signs of dehydration, unexplained fever, severe abdominal pain, or a sweet fruity odour (particularly if you have diabetes), as these may indicate conditions requiring medical assessment.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
